Learn about how we continue to deliver on our commitment to the patient communities we serve and our forward-looking vision for 2025 as shared by our CEO, Catherine Owen Adams at the annual @jpmorgan Healthcare Conference: #JPM25

We’re attending Contemporary Neurology 2025 this week hosted by @NeuroAmerica. We’re looking forward to connecting with the community and discussing the latest in diagnosing, treating, and managing patients with neurological conditions. Learn more: #CN2025

Learn about the latest on our #RettSyndrome treatment and plans for our CNS and #raredisease candidates – as shared by our CEO, Catherine Owen Adams, today at the 43rd Annual @JPMorgan Healthcare Conference:

Today we announced that we’ve submitted a Marketing Authorization Application to the European Medicines Agency for our treatment for #RettSyndrome, underscoring our continued commitment to the Rett community. Learn more:

We’re heading to France to attend the 34th Congress of the French Society of Pediatric Neurology where we’ll be presenting our latest data in #RettSyndrome. Learn more and register here:

We’re looking forward to joining fellow industry leaders at the 43rd Annual @JPMorgan Healthcare Conference next week. Be sure to catch our CEO, Catherine Owen Adams, share our company updates on Tuesday at 9:00 a.m. PT. Tune in live here:

Our CEO, Catherine Owen Adams will be presenting at the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco on Tuesday, January 14, 2025, at 9:00 a.m. PT. Learn more about our participation here:

This past weekend we had the opportunity to share our latest #RettSyndrome research with the epilepsy community at #AES2024. Thank you to the @AmEpilepsySoc for providing an engaging forum to connect with healthcare providers, scientists, advocates, and industry leaders.

Today we announced that Thomas Andrew Garner has been appointed Chief Commercial Officer. He will spearhead Acadia's commercial strategy and operations in addition to serving on the executive leadership team. Learn more:

This weekend, we’re looking forward to attending @ACNPorg 63rd Annual Meeting. This event will bring together top leaders to explore the latest advancements in both neuroscience and psychopharmacology. Learn more and register here:

We’re heading to Los Angeles, CA this week to attend the @AmEpilepsySoc 2024 Annual Meeting where we’ll be sharing our recent #RettSyndrome data. Learn more and register here: #AES2024

We're looking forward to connecting with leaders and advocates from the #ParkinsonsDisease community at upcoming events hosted by @ParkinsonDotOrg, Parkinson’s Association of San Diego, & Parkinson’s Study Group.

Today we announced an exclusive license agreement with Saniona for the development of SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the body. Read more here:

We’re looking forward to participating at two upcoming #investor conferences: Citi's 2024 Global Healthcare Conference & 7th Annual Evercore HealthCONx Conference. Learn about our participation: $ACAD

We’re heading to Spain to present data on #RettSyndrome at #ISPOREurope. We appreciate the opportunity to connect with researchers focused on advancing scientific evidence in understanding & improving the health and well-being of people across the globe.

We look forward to joining the 53rd @ChildNeuroSoc Annual Meeting next week here in San Diego, CA, where we will be connecting with researchers on the latest advancements in child neurology. Learn more: #CNSAM

Today, we shared our Q3 2024 #earnings results. Read our $ACAD financial summary and key updates here:

We’re attending the 20th annual @neiglobal #NEICongress and look forward to discussing our latest findings in #ParkinsonsDisease with professionals in psychiatry and mental health during this enriching educational event. Learn more:

We’re looking forward to attending the 37th Psych Congress this week where we’ll have the opportunity to share our latest #ParkinsonsDisease research with the mental health community. Learn more and register here:

Today we announced that Health Canada has granted marketing authorization for our #RettSyndrome treatment, the first and only drug approved in Canada for the treatment of Rett syndrome. Learn more: